Shire's Vyvanse wins 1st 'binge-eating' indication

Shire picked up another indication for Vyvanse (lisdexamfetamine dimesylate) – winning the first approval in the US for a drug to help curb episodes of binge-eating in adults with the disorder.

More from Alimentary/Metabolic

More from Therapy Areas